PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH INTEGRATION OF EXPLORATIVE MULTI-OMICS AND EX VIVO DRUG SCREENING DATA

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510415-19-00

Enrollment

147

Registered

2024-08-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Brief summary

ORR (including CR/CRh/CRi/MLFS rate, composite CR/CRh/CRi rate, PR rate).

Detailed description

Overall survival (OS), duration of response (DOR), progression free survival (PFS)., Frequency and severity of adverse events (hematologic toxicities-AE grade 3+4, febrile neutropenia, days until neutrophil recovery ≥ 0.5 x 10E9/l and platelet recovery ≥ 50 x 10E9/l, severe AE grade 3+4).

Interventions

DRUGAZACITIDINE

DRUGVENETOCLAX

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
ORR (including CR/CRh/CRi/MLFS rate, composite CR/CRh/CRi rate, PR rate).	—

Secondary

Measure	Time frame
Overall survival (OS), duration of response (DOR), progression free survival (PFS)., Frequency and severity of adverse events (hematologic toxicities-AE grade 3+4, febrile neutropenia, days until neutrophil recovery ≥ 0.5 x 10E9/l and platelet recovery ≥ 50 x 10E9/l, severe AE grade 3+4).	—

Countries

Denmark, Finland, Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026